WCM Investment Management LLC Sells 9,740 Shares of Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE)

WCM Investment Management LLC cut its holdings in Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE - Free Report) by 6.7% in the 4th quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 135,609 shares of the biopharmaceutical company's stock after selling 9,740 shares during the period. WCM Investment Management LLC owned about 0.15% of Ultragenyx Pharmaceutical worth $5,732,000 at the end of the most recent quarter.

Several other institutional investors also recently modified their holdings of the business. Alkeon Capital Management LLC grew its holdings in Ultragenyx Pharmaceutical by 34.3% during the third quarter. Alkeon Capital Management LLC now owns 3,011,716 shares of the biopharmaceutical company's stock valued at $167,301,000 after purchasing an additional 769,884 shares during the period. Two Sigma Advisers LP grew its holdings in Ultragenyx Pharmaceutical by 123.4% during the third quarter. Two Sigma Advisers LP now owns 987,800 shares of the biopharmaceutical company's stock valued at $54,872,000 after purchasing an additional 545,600 shares during the period. Frazier Life Sciences Management L.P. grew its holdings in Ultragenyx Pharmaceutical by 49.1% during the third quarter. Frazier Life Sciences Management L.P. now owns 633,715 shares of the biopharmaceutical company's stock valued at $35,203,000 after purchasing an additional 208,715 shares during the period. Ikarian Capital LLC bought a new position in Ultragenyx Pharmaceutical during the third quarter valued at $9,943,000. Finally, Point72 Asset Management L.P. grew its holdings in Ultragenyx Pharmaceutical by 35.9% during the third quarter. Point72 Asset Management L.P. now owns 653,660 shares of the biopharmaceutical company's stock valued at $36,311,000 after purchasing an additional 172,711 shares during the period. 97.67% of the stock is owned by institutional investors.

Insider Buying and Selling at Ultragenyx Pharmaceutical

In other Ultragenyx Pharmaceutical news, CEO Emil D. Kakkis sold 11,727 shares of the firm's stock in a transaction dated Monday, December 30th. The stock was sold at an average price of $42.23, for a total transaction of $495,231.21. Following the sale, the chief executive officer now owns 2,183,985 shares in the company, valued at $92,229,686.55. This trade represents a 0.53 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available at this hyperlink. Company insiders own 5.80% of the company's stock.

Ultragenyx Pharmaceutical Stock Up 0.2 %

Shares of RARE stock traded up $0.09 on Thursday, reaching $43.52. The company's stock had a trading volume of 784,284 shares, compared to its average volume of 897,117. Ultragenyx Pharmaceutical Inc. has a 12-month low of $37.02 and a 12-month high of $60.37. The company has a market capitalization of $4.02 billion, a P/E ratio of -6.73 and a beta of 0.60. The stock's 50 day simple moving average is $43.81 and its 200-day simple moving average is $49.59.

Ultragenyx Pharmaceutical (NASDAQ:RARE - Get Free Report) last released its quarterly earnings results on Thursday, February 13th. The biopharmaceutical company reported ($1.39) earnings per share for the quarter, missing analysts' consensus estimates of ($1.32) by ($0.07). Ultragenyx Pharmaceutical had a negative net margin of 106.93% and a negative return on equity of 187.12%. Research analysts expect that Ultragenyx Pharmaceutical Inc. will post -6.12 EPS for the current year.

Analyst Upgrades and Downgrades

Several brokerages have weighed in on RARE. JPMorgan Chase & Co. reduced their price objective on Ultragenyx Pharmaceutical from $105.00 to $102.00 and set an "overweight" rating for the company in a report on Thursday, November 21st. Wedbush restated a "neutral" rating and set a $48.00 target price (up previously from $46.00) on shares of Ultragenyx Pharmaceutical in a research report on Monday, January 13th. Cantor Fitzgerald restated an "overweight" rating and set a $118.00 target price on shares of Ultragenyx Pharmaceutical in a research report on Wednesday, January 22nd. Royal Bank of Canada restated an "outperform" rating and set a $77.00 target price on shares of Ultragenyx Pharmaceutical in a research report on Wednesday, November 6th. Finally, Canaccord Genuity Group restated a "buy" rating and set a $121.00 target price on shares of Ultragenyx Pharmaceutical in a research report on Tuesday, November 12th. One analyst has rated the stock with a hold rating and thirteen have given a buy rating to the stock. According to MarketBeat, the company presently has a consensus rating of "Moderate Buy" and a consensus price target of $92.43.

Ultragenyx Pharmaceutical Company Profile

Ultragenyx Pharmaceutical Inc, a biopharmaceutical company, focuses on the identification, acquisition, development, and commercialization of novel products for the treatment of rare and ultra-rare genetic diseases in North America, Latin America, Japan, Europe, and internationally. Its biologic products include Crysvita (burosumab), an antibody targeting fibroblast growth factor 23 for the treatment of X-linked hypophosphatemia, as well as tumor-induced osteomalacia; Mepsevii, an enzyme replacement therapy for the treatment of children and adults with Mucopolysaccharidosis VII; Dojolvi for treating long-chain fatty acid oxidation disorders; and Evkeeza (evinacumab) for the treatment of homozygous familial hypercholesterolemia.